Research Services
Research Library
|
|
EMD Chemicals Inc.
|
Cyclooxygenases (COXs), also known as prostaglandin H synthases, are fatty acid oxygenases that contain about 600 amino acid residues and act on arachidonic acid to generate prostaglandins (PG). All vertebrates contain two COX genes: one encoding the constitutive COX-1 and another inducible COX-2. COX-1 and COX-2 share approximately 60-65% amino acid identity. These COX isoforms are bifunctional ...
|
|
|
PRA International
|
Hepatic impairment trials are generally included as part of the clinical development of a drug. This whitepaper, based on years of experience executing hepatic trials, provides practical information for pharma and biotech professionals. In this whitepaper, you’ll gain knowledge of:
- Similarities and differences between FDA and EMEA guidance on hepatic trials.
- Categorization standards ...
|
|
|
Covance
|
Historically, vaccines are medicines that deliver or generate antigens that induce specic, active, and protective immunity against infectious diseases. Antigens stimulate the immune system to activate cells and organs that induce active immunity, characterized by production of antibodies (humoral immunity) and/or cytotoxic T-cells (cell mediated immunity). Vaccines “train” the body’s immune ...
|
|
|
BIOCIUS Life Sciences (formerly BioTrove RapidFire)
|
Cytochrome P450s (CYP450) mediate the biotransformation of drug compounds. Metabolism of multiple test compounds by the same CYP450 isoform can alter reaction kinetics and result in adverse drug-drug interactions (DDI). Therefore, high throughput-DDI assays are valuable tools in the go/no-go decision-making process in drug discovery. Mass spectrometry-based CYP450 assays have emerged as the ...
|
|
|
GVK Biosciences Private Limited
|
Recent industry analyst reports predict that worldwide pharmaceutical industry revenues will grow at a compound annual growth rate (CAGR) of 8.58% through 2008. Worldwide biotechnology revenues are expected to grow at a compound annual growth rate of 25.96% through 2008 – this large growth rate is not surprising as many biotechnology and biopharmaceutical companies are just now moving products ...
|
|
|
|
